Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19

NCT04350593 is registered in ClinicalTrials.gov with Saint Luke's Health System as lead sponsor.

NCT NCT04350593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04350593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19
Lead sponsor
Saint Luke's Health System
Phase
Phase 3
Overall status
Completed
Start date
April 22, 2020
Completion date
June 11, 2021
Enrollment
1,250 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19